AccuTheranostics, Inc.

AccuTheranostics, Inc. offers a full line of laboratory tests designed to provide information to tailor treatment to the individual patient's cancer. This information enables physicians to avoid the use of specific chemotherapy agents to which the patient's tumor is resistant and select those that will be most effective. AccuTheranostics flagship service is an innovative laboratory test called ChemoFit™ which is a specialized chemosensitive/chemoresistance assay that uses a patient's own tumor cells in the laboratory to identify which drugs have the most, as well as the least, potential for treating the patient's unique cancer. The patient's tumor cells undergo mechanical disaggregation, are subjected to drugs, single and in combination, and a chemo-resistance/sensitivity profile is determined.